Developer docs
API playgroundTry for free, no card

Search company profiles

Valeo Pharma

Full company profile

uuid000534d

Namestring
Valeo Pharma
Legal namestring
Valeo Pharma Inc.
Websiteurl
valeopharma.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Valeo Pharma Inc. is a publicly traded Canadian specialty pharmaceutical company headquartered in Kirkland, Quebec, that licenses and acquires Canadian commercial rights to innovative, commercial-stage prescription drugs from international pharmaceutical partners. The company operates dedicated business units across three primary therapeutic areas — Respiratory/Allergy, Ophthalmology, and Specialty Products — with an additional focus on Neurology (Onstryv/safinamide for Parkinson's disease) and Oncology. Its portfolio of 12 commercialized products includes Enerzair Breezhaler and Atectura Breezhaler (asthma therapies), Redesca/Redesca HP (a low molecular weight heparin biosimilar with over 50% Canadian market share), Xiidra and Simbrinza (ophthalmology, licensed from Novartis), Allerject (epinephrine auto-injector, licensed from Kaléo), and Onstryv. Products are acquired through licensing and supply agreements rather than internal R&D, with key partners including Novartis Pharmaceuticals Canada (7-year agreement signed July 2022), Kaléo Inc., and previously Veru Inc. (agreement mutually terminated May 2023).

The company's commercialization model relies on a dedicated field sales force and marketing team that engages Canadian physicians directly across general practice and specialty channels, supported by a business-unit structure per therapeutic area. Revenue is generated through product sales to Canadian pharmacies and healthcare providers, with pricing substantially determined by provincial drug reimbursement programs including Quebec's RAMQ, the Ontario Drug Benefit Program, Manitoba Pharmacare, the Saskatchewan Drug Plan, the BC Ministry of Health, and federal NIHB and VAC programs. Valeo reported record fiscal 2023 (year ended October 31, 2023) revenues of $54 million CAD, up 94% over $27.7 million in fiscal 2022, with adjusted gross profit of $16.9 million (+80% YoY) but an adjusted EBITDA loss of $10.9 million reflecting continued investment in commercialization, sales infrastructure, and new product launches.

The company listed on the Toronto Stock Exchange (VPH) in March 2022 and has funded its growth through a US$30 million secured term loan from Sagard Healthcare Partners (July 2022), a $4.5 million private placement led by Investissement Québec (August 2023), and a $5 million credit facility from Accord Financial (September 2023). Leadership was strengthened in 2023 with the appointments of Pascal Tougas as CFO (replacing Luc Mainville) and board additions including former Bausch Health Canada and Alcon Canada presidents. The company also announced organizational changes and cost reduction initiatives in November 2023 targeting more than $2 million in annual savings.

Short descriptiontext

Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription drugs across respiratory, ophthalmology, and specialty therapeutic areas in Canada, serving physicians and patients through a dedicated national field sales force and pharmacy distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKirkland, Canada
HQ citystring
Kirkland
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, prescription drug commercialization, respiratory therapeutics, ophthalmology medications, pharmaceutical licensing
Industry3 codes
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeTransaction Fee
Description

Valeo Pharma generates revenue through the sale of commercialized prescription pharmaceutical products including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv across therapeutic areas of respiratory/allergy, ophthalmology, and specialty products.

valeopharma.com
2Working Capital and Growth Financing
TypeTransaction Fee
Description

The company secured a $5 million credit facility with Accord Financial Inc. and completed a $4.5 million private placement financing to support working capital and growth initiatives.

valeopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Prescription pharmaceutical products sold through pharmacies and healthcare providers
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

Products are sold as prescription medications through Canadian pharmacies. Pricing is subject to public reimbursement coverage decisions by provincial drug plans (RAMQ, Ontario Drug Benefit, etc.) and varies by province.

valeopharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and acquires Canadian commercial rights to innovative, proprietary prescription drugs from international pharmaceutical partners, and commercializes them through its own field sales force, marketing teams, and dedicated business units in respiratory/allergy, ophthalmology, and specialty therapeutic areas. The company's portfolio consists of 12 commercialized products, including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Revenue growth of 94% year-over-year to $54 million in fiscal 2023
+4 more records
Product overview1 text field

Valeo Pharma is a Canadian pharmaceutical company commercializing innovative prescription products across five therapeutic areas: Respiratory/Allergy, Ophthalmology, Specialty Products, Neurology, and Oncology. The company's portfolio consists of 12 commercialized products including core brands Enerzair Breezehaler and Atectura Breezhaler (asthma therapies), Redesca (anticoagulant biosimilar), Xiidra and Simbrinza (ophthalmology), Allerject (epinephrine auto-injector), and Onstryv (Parkinson's disease treatment). Products are acquired through licensing and partnership agreements with international pharmaceutical companies and commercialized in the Canadian market. The company operates a focused commercial model with dedicated business units for each therapeutic area.

Product and service7 records
1Enerzair Breezhaler
CategoryRespiratory / Allergy Pharmaceuticals
Description

Innovative single maintenance and reliever asthma therapy (triple-active) commercialized in Canada through the Breezhaler inhaler device. Marketed as a leading drug in Canada's fast-growing triple-active asthma market, promoted through dedicated physician engagement programs.

2Atectura Breezhaler
CategoryRespiratory / Allergy Pharmaceuticals
Description

Respiratory therapy for asthma management, used as an asthma control medication for patients requiring additional treatment options. Commercialized in Canada through the Breezhaler inhaler device.

3Redesca / Redesca HP
CategorySpecialty Pharmaceuticals
Description

Low molecular weight heparin (LMWH) biosimilar anticoagulant for Canadian patients. Leads the LMWH biosimilar market in Canada with more than 50% market share. Available in standard and HP (high potency) presentations.

4Xiidra
CategoryOphthalmology Pharmaceuticals
Description

Prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease. Ophthalmology product acquired through partnership with Novartis for Canadian commercialization.

5Simbrinza
CategoryOphthalmology Pharmaceuticals
Description

Prescription ophthalmology therapy for the treatment of eye conditions such as glaucoma. Acquired through a 7-year Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian market.

6Allerject
CategoryRespiratory / Allergy Pharmaceuticals
Description

Epinephrine injection, USP auto-injector for the emergency treatment of serious allergic reactions including anaphylaxis. Commercialized in Canada under a license from Kaléo Inc., with promotional launch activities in April 2023.

7Onstryv (safinamide)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-07-04
Description

Valeo entered into a 7-year Commercialization and Supply Agreement with Novartis for Canadian rights to XIIDRA and SIMBRINZA ophthalmic products. Novartis has agreed to sell XIIDRA global rights to Bausch + Lomb, though SIMBRINZA is not included in the divestiture.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-07-01
Description

Valeo entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for Canadian rights to ALLERJECT (epinephrine injection, USP) auto-injector for treatment of serious allergic reactions.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-01
Description

Valeo entered into a Commercial Services Agreement with Veru Inc. for sabizabulin in Canada, a novel dual antiviral and anti-inflammatory agent for COVID-19 treatment. Following FDA rejection of Veru's EUA request for sabizabulin, the agreement was mutually terminated in May 2023.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valeo Pharma

Specialty Pharmaceuticalsvaleopharma.com

Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription drugs across respiratory, ophthalmology, and specialty therapeutic areas in Canada, serving physicians and patients through a dedicated national field sales force and pharmacy distribution.

What Valeo Pharma does

Valeo Pharma Inc. is a publicly traded Canadian specialty pharmaceutical company headquartered in Kirkland, Quebec, that licenses and acquires Canadian commercial rights to innovative, commercial-stage prescription drugs from international pharmaceutical partners. The company operates dedicated business units across three primary therapeutic areas — Respiratory/Allergy, Ophthalmology, and Specialty Products — with an additional focus on Neurology (Onstryv/safinamide for Parkinson's disease) and Oncology. Its portfolio of 12 commercialized products includes Enerzair Breezhaler and Atectura Breezhaler (asthma therapies), Redesca/Redesca HP (a low molecular weight heparin biosimilar with over 50% Canadian market share), Xiidra and Simbrinza (ophthalmology, licensed from Novartis), Allerject (epinephrine auto-injector, licensed from Kaléo), and Onstryv. Products are acquired through licensing and supply agreements rather than internal R&D, with key partners including Novartis Pharmaceuticals Canada (7-year agreement signed July 2022), Kaléo Inc., and previously Veru Inc. (agreement mutually terminated May 2023).

The company's commercialization model relies on a dedicated field sales force and marketing team that engages Canadian physicians directly across general practice and specialty channels, supported by a business-unit structure per therapeutic area. Revenue is generated through product sales to Canadian pharmacies and healthcare providers, with pricing substantially determined by provincial drug reimbursement programs including Quebec's RAMQ, the Ontario Drug Benefit Program, Manitoba Pharmacare, the Saskatchewan Drug Plan, the BC Ministry of Health, and federal NIHB and VAC programs. Valeo reported record fiscal 2023 (year ended October 31, 2023) revenues of $54 million CAD, up 94% over $27.7 million in fiscal 2022, with adjusted gross profit of $16.9 million (+80% YoY) but an adjusted EBITDA loss of $10.9 million reflecting continued investment in commercialization, sales infrastructure, and new product launches.

The company listed on the Toronto Stock Exchange (VPH) in March 2022 and has funded its growth through a US$30 million secured term loan from Sagard Healthcare Partners (July 2022), a $4.5 million private placement led by Investissement Québec (August 2023), and a $5 million credit facility from Accord Financial (September 2023). Leadership was strengthened in 2023 with the appointments of Pascal Tougas as CFO (replacing Luc Mainville) and board additions including former Bausch Health Canada and Alcon Canada presidents. The company also announced organizational changes and cost reduction initiatives in November 2023 targeting more than $2 million in annual savings.

Valeo Pharma firmographics

Firmographics
Name
Valeo Pharma
Legal name
Valeo Pharma Inc.
Website
https://valeopharma.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription drugs across respiratory, ophthalmology, and specialty therapeutic areas in Canada, serving physicians and patients through a dedicated national field sales force and pharmacy distribution.
Ownership category
akta.pro rank

Valeo Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution

Keywords

  • Specialty pharmaceuticals
  • Prescription drug commercialization
  • Respiratory therapeutics
  • Ophthalmology medications
  • Pharmaceutical licensing

Where Valeo Pharma is headquartered

Location

Headquarters

HQ city
Kirkland
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Valeo Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Valeo Pharma generates revenue through the sale of commercialized prescription pharmaceutical products including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv across therapeutic areas of respiratory/allergy, ophthalmology, and specialty products.
  2. Working Capital and Growth Financing: The company secured a $5 million credit facility with Accord Financial Inc. and completed a $4.5 million private placement financing to support working capital and growth initiatives.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goPrescription pharmaceutical products sold through pharmacies and healthcare providers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Valeo Pharma product offering

Product offering

Core offering

Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and acquires Canadian commercial rights to innovative, proprietary prescription drugs from international pharmaceutical partners, and commercializes them through its own field sales force, marketing teams, and dedicated business units in respiratory/allergy, ophthalmology, and specialty therapeutic areas. The company's portfolio consists of 12 commercialized products, including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv.

Product overview

Valeo Pharma is a Canadian pharmaceutical company commercializing innovative prescription products across five therapeutic areas: Respiratory/Allergy, Ophthalmology, Specialty Products, Neurology, and Oncology. The company's portfolio consists of 12 commercialized products including core brands Enerzair Breezehaler and Atectura Breezhaler (asthma therapies), Redesca (anticoagulant biosimilar), Xiidra and Simbrinza (ophthalmology), Allerject (epinephrine auto-injector), and Onstryv (Parkinson's disease treatment). Products are acquired through licensing and partnership agreements with international pharmaceutical companies and commercialized in the Canadian market. The company operates a focused commercial model with dedicated business units for each therapeutic area.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enerzair Breezhaler Innovative single maintenance and reliever asthma therapy (triple-active) commercialized in Canada through the Breezhaler inhaler device. Marketed as a leading drug in Canada's fast-growing triple-active asthma market, promoted through dedicated physician engagement programs.
  • Atectura Breezhaler Respiratory therapy for asthma management, used as an asthma control medication for patients requiring additional treatment options. Commercialized in Canada through the Breezhaler inhaler device.
  • Redesca / Redesca HP Low molecular weight heparin (LMWH) biosimilar anticoagulant for Canadian patients. Leads the LMWH biosimilar market in Canada with more than 50% market share. Available in standard and HP (high potency) presentations.
  • Xiidra Prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease. Ophthalmology product acquired through partnership with Novartis for Canadian commercialization.
  • Simbrinza Prescription ophthalmology therapy for the treatment of eye conditions such as glaucoma. Acquired through a 7-year Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian market.
  • Allerject Epinephrine injection, USP auto-injector for the emergency treatment of serious allergic reactions including anaphylaxis. Commercialized in Canada under a license from Kaléo Inc., with promotional launch activities in April 2023.
  • Onstryv (safinamide)

Quantifiable outcome

  • Revenue growth of 94% year-over-year to $54 million in fiscal 2023
  • +4 more outcomes

Companies that use Valeo Pharma

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles1 record

Valeo Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Valeo Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Novartis Pharmaceuticals Canada Inc.coreOEM/ Whitelabel/ Licensing Partner · 4 July 2022Valeo entered into a 7-year Commercialization and Supply Agreement with Novartis for Canadian rights to XIIDRA and SIMBRINZA ophthalmic products. Novartis has agreed to sell XIIDRA global rights to Bausch + Lomb, though SIMBRINZA is not included in the divestiture.
  • Kaléo Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 July 2022Valeo entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for Canadian rights to ALLERJECT (epinephrine injection, USP) auto-injector for treatment of serious allergic reactions.
  • Veru Inc.minorStrategic or Co-development Partner · 1 July 2022Valeo entered into a Commercial Services Agreement with Veru Inc. for sabizabulin in Canada, a novel dual antiviral and anti-inflammatory agent for COVID-19 treatment. Following FDA rejection of Veru's EUA request for sabizabulin, the agreement was mutually terminated in May 2023.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Valeo Pharma competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Valeo Pharma social profiles

Digital presence

Valeo Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valeo Pharma leadership team

Management profile

Number of profiles

Profiles13 records

Valeo Pharma funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valeo Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valeo Pharma

What does Valeo Pharma do?

Valeo Pharma is a Canadian specialty pharmaceutical company that licenses and acquires Canadian commercial rights to innovative, proprietary prescription drugs from international pharmaceutical partners, and commercializes them through its own field sales force, marketing teams, and dedicated business units in respiratory/allergy, ophthalmology, and specialty therapeutic areas. The company's portfolio consists of 12 commercialized products, including Enerzair, Atectura, Redesca, Xiidra, Simbrinza, Allerject, and Onstryv.

Is Valeo Pharma a public or private company?

Valeo Pharma is a public company. It is classified as public and is currently operating.

When was Valeo Pharma founded?

Valeo Pharma was founded in 2003. It employs 11 to 50 people.

Where is Valeo Pharma based?

Valeo Pharma is headquartered in Kirkland, Canada, in the North America region.

How does Valeo Pharma make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are working Capital and Growth Financing.

Does Valeo Pharma have an API?

No public API is recorded for Valeo Pharma.

What industry is Valeo Pharma in?

Valeo Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooValeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.Valeo Pharma Inc. completed a share purchase agreement with Xediton Pharmaceuticals Inc. as part of its proceedings under the Companies' Creditors Arrangement Act. The transaction involved the acquisition of 100% of Valeo by Xediton, including its licenses, agreements, and subsidiaries, but with no recovery for previous shareholders.The Globe and MailValeo Pharma: Top 25 Undervalued Toronto Stock Exchange Stocks (VPH)Valeo Pharma is ranked among the top 25 undervalued Toronto Stock Exchange stocks, with a valuation difference of 130.6% and a market capitalization of $26.21 billion. The company operates in branded prescription products and hospital specialty products, covering respiratory, ophthalmology, neurology, and oncology.The Globe and MailValeo Pharma: Top 10 Undervalued Healthcare Sector Stocks on TSX (VPH)Valeo Pharma is ranked among the top 10 undervalued healthcare stocks on the TSX, trading at a 102.6% discount to its valuation. The company, a Canadian specialty pharmaceutical firm, operates in branded prescription and hospital specialty products, with a portfolio covering respiratory, ophthalmology, neurology, and oncology.ValeopharmaVALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.Valeo Pharma Inc. has entered into a $5 million credit facility agreement with Accord Financial Inc., secured by a first-rank lien on the company's short-term assets. The borrowed funds are designated for working capital and general corporate purposes to support long-term growth and profitability.NewswireVALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.Valeo Pharma Inc. has entered into a $5 million credit facility agreement with Accord Financial Inc., secured by a first-rank lien on the company's short-term assets. The borrowed funds are designated for working capital and general corporate purposes to support long-term growth and profitability. This move provides Valeo with additional financial liquidity through non-dilutive capital.MarketScreenerValeo Pharma secures $5M credit facility agreement with Accord FinancialValeo Pharma has secured a $5 million credit facility agreement with Accord Financial to support its rapid growth trajectory. The capital, backed by a lien on short-term assets and carrying interest at the prime rate plus a margin, allows the company to expand without resorting to share dilution. This strategic move aims to meet rising demand for innovative pharmaceutical products in Canada while preserving shareholder value.NewswireVALEO PHARMA CLOSES $4.5 MILLION FINANCINGValeo Pharma Inc. closed a $4.5 million financing on August 31, 2023, consisting of a non-brokered private placement offering that raised $3.92 million and an additional loan of $0.58 million. The financing included $2.0 million from Investissement Québec and aims to strengthen the company's working capital and support its growth initiatives. The investment reflects confidence in Valeo's business strategy within the life sciences sector in Quebec.ValeopharmaVALEO PHARMA CLOSES $4.5 MILLION FINANCINGValeo Pharma Inc. closed a $4.5 million financing package comprising a $3.92 million non-brokered private placement and a $580,000 insider loan to strengthen its working capital. Investissement Québec contributed $2.0 million to the offering, demonstrating confidence in the company's growth strategy and market share expansion plans.